688266 Share Price Performance
CN¥113.01
39.00 (52.70%)
Price CN¥113.01
Share PriceCN¥113.01
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Mar 03
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
688266 Community Narratives
There are no narratives available yet.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 31, 2025
- Earnings per share (EPS)
- -0.54
- Gross Margin
- 90.68%
- Net Profit Margin
- -21.57%
- Debt/Equity Ratio
- 94.9%
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Competitors
Snowflake Analysis
About 688266
- Founded
- 2009
- Employees
- 910
- CEO
- WebsiteView website
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 1.8%
- 3 Months: 18.3%
- 1 Year: 24.1%
- Year to Date: 26.2%
The Industrials sector has led the market, which has gained 1.8%. In the last year, the market has climbed 24%. Earnings are forecast to grow by 27% annually. Market details ›